23 completed, 3 unknown, 2 withdrawn, 1 terminated. 29 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 29 | Completed 23, Unknown 3, Withdrawn 2, Terminated 1 |
Follow Allergic Conjunctivitis: new trials by email Literature Review of Allergic Conjunctivitis trials Research Report on Allergic Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL, azelastine hydrochloride 0.05% - Allergic Conjunctivitis, Dry Eye Disease (DED) | Phase 4 | Completed | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | 134 | 2023-04-21 | 2025-07-15 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 61 | 2021-12-31 | 2022-09-02 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 58 | 2021-12-14 | 2022-05-03 |
| Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK - Allergic Conjunctivitis | Phase 4 | Completed | Laboratorios Poen | 97 | 2021-03-10 | 2022-12-15 |
| Manuka Eye Droops for Treatment of Allergy Manuka honey - Allergic Conjunctivitis | Phase 4 | Withdrawn | Toyos Clinic | 2020-01-01 | 2020-10-09 | |
| A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Lastacaft ®, Tears Naturale ® (Placebo) - Allergic Conjunctivitis | Phase 4 | Completed | ORA, Inc. | 25 | 2014-12-01 | 2021-03-18 |
| Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05% - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 50 | 2013-12-01 | 2015-10-07 |
| Ocular Allergy Treatment Practical Impact Trial Alcaftadine - Allergic Conjunctivitis, Rhinoconjunctivitis | Phase 4 | Unknown | Starx Research Center, LLC | 50 | 2013-04-01 | 2013-05-30 |
| Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Olopatadine hydrochloride ophthalmic solution, 0.2% - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 17 | 2012-09-01 | 2014-08-18 |
| Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Prednisolone Sodium Phosphate Ophthalmic Solution 1%, Tears Naturale II Ophthalmic Solution - Allergic Conjunctivitis | Phase 4 | Completed | ORA, Inc. | 11 | 2012-01-01 | 2019-03-26 |
| Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis bepotastine besilate, 1.5%, Loteprednol etabonate - Allergic Conjunctivitis | Phase 4 | Completed | Southern California College of Optometry at Marshall B. Ketchum University | 23 | 2011-10-01 | 2019-08-06 |
| An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Fluticasone Propionate Nasal Spray, Saline Nasal Spray - Allergic Rhinitis, Allergic Conjunctivitis | Phase 4 | Completed | ORA, Inc. | 22 | 2011-09-01 | 2021-04-14 |
| Comparison of Tolerability Between Two Allergy Drops alacaftadine and naphazoline HCl & pheniramine maleate - Allergic Conjunctivitis | Phase 4 | Unknown | Hom, Milton M., OD, FAAO | 48 | 2011-08-01 | 2011-07-11 |
| Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Bepotastine - Allergic Conjunctivitis | Phase 4 | Unknown | Hom, Milton M., OD, FAAO | 24 | 2011-05-01 | 2011-04-19 |
| The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Refresh Tears 0.5% Lubricant Eye Drops, Bepreve 1.5% Ophthalmic Solution - Allergic Conjunctivitis | Phase 4 | Completed | Minnesota Eye Consultants, P.A. | 40 | 2011-05-01 | 2020-03-31 |
| A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Olopatadine Hydrochloride Ophthalmic Solution, 0.2% - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 300 | 2011-05-01 | 2012-09-18 |
| Assessment of Alcon's Ocular Image Quantification System Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 13 | 2010-12-01 | 2012-12-18 |
| Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients NAABAK eyedrops, Saline eyedrops - Allergic Conjunctivitis | Phase 4 | Completed | Laboratoires Thea | 21 | 2010-10-01 | 2012-01-31 |
| Patient Perception Study for AL-4943A AL-4943A - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 47 | 2010-09-01 | 2016-12-16 |
| Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®) - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 215 | 2010-06-01 | 2012-04-03 |
Showing 20 of 29. Sign in to see all of them.
Conjunctivitis, Allergic (29) · Conjunctivitis (4) · Hypersensitivity (2) · Asthma (1) · Dermatitis, Atopic (1) · Dry Eye Syndromes (1) · Rhinitis, Allergic (1) · Rhinitis, Allergic, Seasonal (1)
Conjunctival Diseases (29) · Eye Diseases (29) · Hypersensitivity, Immediate (29) · Immune System Diseases (29) · Hypersensitivity (27) · Conjunctivitis (25) · Nose Diseases (2) · Otorhinolaryngologic Diseases (2) · Respiratory Hypersensitivity (2) · Respiratory Tract Diseases (2) · Rhinitis (2) · Bronchial Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dermatitis (1) · Genetic Diseases, Inborn (1)
Olopatadine Hydrochloride (12) · bepotastine besilate (4) · Lubricant Eye Drops (3) · Ophthalmic Solutions (3) · alcaftadine (3) · Fluticasone (2) · Loteprednol Etabonate (2) · epinastine (2) · Dexamethasone (1) · Dextrans (1) · Hypromellose Derivatives (1) · Loratadine (1) · Methylprednisolone (1) · Naphazoline (1) · Naphcon A (1)
Alcon Research (10) · ORA, Inc. (4) · Hom, Milton M., OD, FAAO (3) · Andover Research Eye Institute (2) · Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona (1) · Laboratoires Thea (1) · Laboratorios Poen (1) · Meiji University of Oriental Medicine (1) · Merck Sharp & Dohme LLC (1) · Minnesota Eye Consultants, P.A. (1) · Southern California College of Optometry at Marshall B. Ketchum University (1) · Starx Research Center, LLC (1) · Toyos Clinic (1) · University of Helsinki (1)
United States (14) · Italy (2) · Japan (2) · South Korea (2) · Argentina (1) · Finland (1) · India (1)
Milton M Hom, OD FAAO (2) · Tarek Shazly, MD (2) · Ahmad M Fahmy, O.D. (1) · Christine Sindt, OD, FAAO (1) · Eriko Chono (1) · Gail L Torkildsen, MD (1) · Jayesh Kanuga, MD (1) · Judy Tong, OD (1) · Jun Yamada, M.D. Ph.D. (1) · Junji Hamuro, Ph.D. (1) · Mario Troisi, MD (1) · Michael Raizman, MD (1) · Pam Kaur, MS PhD (1) · Shigeru Kinoshita, M.D. Ph.D. (1) · Tari Haahtela, Professor (1)